Brandon Stahl, MD
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by Astellas Pharma US Inc at 45.0% of the total. Reporting peaked in 2023 at $569 and has fallen 72.2% since, to $158 in 2024.
Across 40 payments — averaging $34.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$625
- Intuitive Surgical$163
- Teleflex LLC$114
- Pfizer$69
- Urovant Sciences Inc$59
- Tolmar Pharmaceuticals, Inc.$42
- plus $316 from 14 others
Across 7 payments — averaging $748.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$5K
Across 4 payments — averaging $10,000 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$40K
What the payments were for
- Food & beverage$71151%
- Education$67749%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $625 |
| Intuitive Surgical | 3 | $163 |
| Teleflex LLC | 1 | $114 |
| Pfizer | 4 | $69 |
| Urovant Sciences Inc | 3 | $59 |
| Tolmar Pharmaceuticals, Inc. | 1 | $42 |
| Medtronic | 2 | $42 |
| KARL Storz Endoscopy-america | 1 | $35 |
| AbbVie | 2 | $35 |
| Coloplast | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Covidien LP | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $14 |
| Axonics, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$114
How this compares
$1,388 in reported general payments places this provider in the 55th percentile of 59 urology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 48 | $46,947 |
| GemtesaVibegron | 29 | $41,422 |
| Mirabegron ErMirabegron | 13 | $9,748 |
| Tamsulosin Hcl | 395 | $6,300 |
| Finasteride | 187 | $2,659 |
| Tadalafil | 22 | $2,446 |
| Potassium Citrate ErPotassium Citrate | 15 | $2,244 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 76 | $1,739 |
| Solifenacin Succinate | 47 | $1,717 |
| Silodosin | 16 | $1,550 |
| Dutasteride | 36 | $1,010 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $391 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $331 |
| Ciprofloxacin Hcl | 69 | $270 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 66 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $625 | $46,94748 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $41,42229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 59 urology providers in Maine.
Other urology in York
- Robert MyersYork$57
- Griffith BatstoneFarmington$123K
- David SobelPortland$58K
- Marc HodroffPortland$17K
- Evan DunnLewiston$9K
- Robert FisherRockport$9K
- Christopher HenryLewiston$6K
- Jesse SammonSouth Portland$6K
- Sanchita BoseSouth Portland$6K
- Michael ParkerLewiston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.